Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): A phase 3 open-label, randomised controlled trial

The Lancet

Volumn 379, Issue 9813, 2012, Pages 315-321

  Bang, Yung Jue ^a   Kim, Young Woo ^b   Yang, Han Kwang ^a   Chung, Hyun Cheol ^d   Park, Young Kyu ^e   Lee, Kyung Hee ^f   Lee, Keun Wook ^g   Kim, Yong Ho ^h   Noh, Sang Ik ⁱ   Cho, Jae Yong ^d   Mok, Young Jae ^j   Kim, Yeul Hong ^j   Ji, Jiafu ^k   Yeh, Ta Sen ^l   Button, Peter ^m   Sirzén, Florin ⁿ   Noh, Sung Hoon ^c  

^a Seoul National University   (South Korea)

^b National Cancer Center   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

^d Yonsei University College of Medicine   (South Korea)

^e Chonnam National University   (South Korea)

^f Yeungnam University College of Medicine   (South Korea)

^g Seoul National University Bundang Hospital   (South Korea)

^h Kyung Hee University Hospital   (South Korea)

ⁱ Seoul Veterans Hospital   (South Korea)

^j Korea University College of Medicine   (South Korea)

^k PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^l CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^m Infopeople   (Australia)

ⁿ F HOFFMANN LA ROCHE LTD   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; OXALIPLATIN;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; ASTHENIA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHINA; CONSTIPATION; CONTROLLED STUDY; DECREASED APPETITE; DISEASE FREE SURVIVAL; DIZZINESS; DRUG EFFICACY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; GASTRECTOMY; HAND FOOT SYNDROME; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OPEN STUDY; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; POSTOPERATIVE CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; SIDE EFFECT; SOUTH KOREA; STOMACH CANCER; STOMATITIS; TAIWAN; THROMBOCYTOPENIA; VOMITING; WEIGHT REDUCTION;

EID: 84856382467     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)61873-4     Document Type: Article

References (31)

1. J Ferlay, HR Shin, F Bray, D Forman, C Mathers, DM Parkin GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 2010 International Agency for Research on Cancer Lyon, France Available from: http://globocan.iarc.fr/factsheets/cancers/stomach.asp (accessed Oct 12, 2011).
2. A Gallo, C Cha Updates on esophageal and gastric cancers World J Gastroenterol 12 2006 3237 3242 (Pubitemid 43881349)
3. LL Gunderson Gastric cancer - patterns of relapse after surgical resection Semin Radiat Oncol 12 2002 150 161 (Pubitemid 34522351)
4. Japanese Gastric Cancer Society Guidelines for Diagnosis and Treatment of Carcinoma of the Stomach http://www.jgca.jp/PDFfiles/Guidelines2004-eng.pdf (accessed Oct 12, 2011).
5. JM Park, YH Kim Current approaches to gastric cancer in Korea Gastrointest Cancer Res 2 2008 137 144
6. A Cuschieri, S Weeden, J Fielding the Surgical Co-operative Group Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial Br J Cancer 79 1999 1522 1530 (Pubitemid 29116815)
7. JJ Bonenkamp, J Hermans, M Sasako the Dutch Gastric Cancer Group Extended lymph-node dissection for gastric cancer N Engl J Med 340 1999 908 914 (Pubitemid 29141051)
8. I Songun, H Putter, EM Kranenbarg, M Sasako, CJ van de Velde Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial Lancet Oncol 11 2010 439 449
9. CW Wu, CA Hsiung, SS Lo et al. Nodal dissection for patients with gastric cancer: a randomised controlled trial Lancet Oncol 7 2006 309 315
10. A Okines, M Verheij, W Allum, D Cunningham, A Cervantes the ESMO Guidelines Working Group Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 21 suppl 5 2010 v50 v54
11. NCCN NCCN Clinical Practice Guidelines in Oncology. Gastric Cancer. Version 2.2011 http://www.nccn.org 2011 (accessed Dec 5, 2011).
12. X Paoletti, K Oba, T Burzykowski the GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis JAMA 303 2010 1729 1737
13. S Sakuramoto, M Sasako, T Yamaguchi the ACTS-GC Group Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine N Engl J Med 357 2007 1810 1820 (Pubitemid 350044801)
14. JS Macdonald, SR Smalley, J Benedetti et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction N Engl J Med 345 2001 725 730
15. D Cunningham, WH Allum, SP Stenning the MAGIC Trial Participants Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer N Engl J Med 355 2006 11 20
16. A Ohtsu, M Sasako Overview of adjuvant therapy for resected gastric cancer: differences in Japan and the United States Semin Oncol 32 suppl 9 2005 S101 S104
17. A Ohtsu, S Yoshida, N Saijo Disparities in gastric cancer chemotherapy between the East and West J Clin Oncol 24 2006 2188 2196 (Pubitemid 46630691)
18. M Sasako, S Sakuramoto, H Katai et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer J Clin Oncol 29 2011 4387 4393
19. A Jatoi, BR Murphy, NR Foster the North Central Cancer Treatment Group Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia: a phase II study from the North Central Cancer Treatment Group Ann Oncol 17 2006 29 34 (Pubitemid 43033836)
20. C Liu, Q Sun, X Hang, B Zhong, D Wang Multicenter phase II study of capecitabine plus oxaliplatin as a first-line therapy in Chinese patients with advanced gastric cancer Anticancer Drugs 19 2008 825 831
21. HY Luo, RH Xu, F Wang et al. Phase II trial of XELOX as first-line treatment for patients with advanced gastric cancer Chemotherapy 56 2010 94 100
22. YH Park, JL Lee, BY Ryoo et al. Capecitabine in combination with oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer Cancer Chemother Pharmacol 61 2008 623 629
23. American Joint Committee on Cancer Cancer Staging Manual 6th ed. 2003 Springer Chicago
24. KKG Lan, DL DeMets Discrete sequential boundaries for clinical trials Biometrika 70 1983 659 663
25. C Jenison, B Turnbull Group sequential methods with applications to clinical trials 2000 Chapman and Hall/CRC Boca Raton
26. J Deng, H Liang, D Wang, D Sun, Y Pan, Y Liu Investigation of the recurrence patterns of gastric cancer following a curative resection Surg Today 41 2011 210 215
27. P Rougier, J Sakamoto Surrogate endpoints for overall survival in resectable gastric cancer and in advanced gastric carcinoma: analysis of individual data from the gastric collaboration Ann Oncol 22 suppl 5 2011 v10 v18 (abstr O-0013).
28. DG Haller, J Tabernero, J Maroun et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer J Clin Oncol 29 2011 1465 1471
29. HJ Schmoll, T Cartwright, J Tabernero et al. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients J Clin Oncol 25 2007 102 109 (Pubitemid 350003057)
30. VE Strong, KY Song, CH Park et al. Comparison of gastric cancer survival following R0 resection in the United States and Korea using an internationally validated nomogram Ann Surg 251 2010 640 646
31. YJ Bang, E Van Cutsem, A Feyereislova the ToGA Trial Investigators Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial Lancet 376 2010 687 697